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1  | BRIEF LOOK AT THE HISTORY OF 
VACCINES:  WHERE WE ARE COMING FROM
Viruses are highly evolved and adapted supramolecular entities 
that take advantage of their host and can be strongly pathogenic.1 
Viruses can cause pathogenesis by their entry and replication in host 
cells. Damage is usually caused by lytic activity of the virus or killing 
infected cells mediated by the immune cells, resulting in excessive 
cell death and inflammation. Hence, early stop of viral spread is the 
goal of most vaccinations.2
The practice of variolation, also called “inoculation or inser-
tion,” was used in China in the 10th century to immunize people 
against smallpox. Live, virulent viruses were collected from scabs 
of infected victims and inserted into the skin of healthy individuals. 
The concept of variolation against smallpox spread further to India 
in the 17th century followed to southwest Asia and Balkans3,4 and 
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Abstract
Vaccines need to be rationally designed in order be delivered to the immune system 
for maximizing induction of dynamic immune responses. Virus-like particles (VLPs) are 
ideal platforms for such 3D vaccines, as they allow the display of complex and native 
antigens in a highly repetitive form on their surface and can easily reach lymphoid 
organs in intact form for optimal activation of B and T cells. Adjusting size and zeta 
potential may allow investigators to further fine-tune delivery to lymphoid organs. An 
additional way to alter vaccine transfer to lymph nodes and spleen may be the for-
mulation with micron-sized adjuvants that creates a local depot and results in a slow 
release of antigen and adjuvant. Ideally, the adjuvant in addition stimulates the innate 
immune system. The dynamics of the immune response may be further enhanced by 
inclusion of Toll-like receptor ligands, which many VLPs naturally package. Hence, con-
sidering the 3Ds in vaccine development may allow for enhancement of their attributes 
to tackle complex diseases, not usually amenable to conventional vaccine strategies.
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even to London by Lady Mary Montagu.5 Variolation was consid-
ered the sole practice to induce protection against smallpox until 
1796 when Edward Jenner tested his hypothesis that pus from 
blisters from cowpox-infected milkmaids can protect against small-
pox. Jenner inoculated an 8-year-old boy, James Phipps, in both 
arms with this cow-derived virus, causing the boy to develop some 
mild symptoms. Later, he challenged the boy with smallpox (by way 
of variolation), and there were no signs of disease.6,7 The method 
was termed vaccination from the Latin word vacca, which means 
cow, and was much safer with milder reactions than variolation 
(which caused up to 1% death) and no risk of disease transmission.8 
Mass vaccination against smallpox, finally pioneered by the World 
Health Organization, resulted in eventual global eradication of the 
disease by 1979. While the world has seen many more vaccines 
with improved safety profiles, no subsequent vaccine ever reached 
the efficacy of vaccinia-based vaccination. The next vaccine hall-
mark occurred with the revolutionizing work of Louis Pasteur for 
the development of an attenuated cholera vaccine in 1897 and 
inactivated anthrax vaccine in 1904 for humans. Both were pro-
duced in laboratories rather than by straight isolation from humans 
or cows as it was the case for vaccinia virus. Vaccination against vi-
ruses represented more of a challenge to Pasteur than vaccination 
against bacteria, most likely because viruses required cell culture 
techniques not yet developed. Nevertheless, Pasteur could suc-
cessfully protect dogs from rabies as well as a 9-year-old boy who 
had been severely attacked by infected dogs with a vaccine that 
was, however, produced in the brain of infected rabbits.9 In the late 
19th century, a vaccine against plague (Yersinia pestis) was started 
by Alexandre Yersin based on killed whole-cell bacteria. However, 
the vaccine proved less efficacious against the most severe pneu-
monia form of plague.10 For this reason and due to re-emergence 
of plague, efforts are currently made to develop more effective 
vaccines against plague based on attenuated bacteria and recom-
binant proteins.11 The development of a vaccine against tubercu-
losis occurred during the period of 1890 to 1950. At the end of 
the 19th century, Calmette and Guérin started their research for 
a vaccine against tuberculosis at the Pasteur Institute, resulting in 
the Bacillus Calmette-Guérin (BCG) vaccine strain.12 The efficacy 
of this BCG vaccine is still controversial, despite the fact that live 
BCG is in use as a vaccine against TB in humans in some parts of 
the world where it seems to attenuate severe forms of TB.13,14
The Salk vaccine “inactivated poliovirus” was developed by Jonas 
Salk in the 1950s, while the Sabin vaccine “live attenuated poliovi-
rus” was advanced by Albert Sabin for oral administration. Though 
highly efficacious, the Sabin vaccine is only used rarely nowadays 
due to the potential to revert to a virulent form or cause disease in 
immunocompromised individuals. Mass immunization against polio-
virus resulted in the eradication of the disease in most parts of the 
world.15 The widely used “MMR” vaccines against “measles, mumps, 
and rubella” have been developed using attenuated viruses.16 The 
MMR vaccine has massively reduced the presence of these viruses 
in our society and, in terms of safety and, portrays a positive bene-
fit-risk profile.17 Vaccines may not only be used to protect against 
different pathogens, but they also play an important role in the treat-
ment of allergies.18 Furthermore, and perhaps with the brightest fu-
ture, a large number of therapeutic vaccines are currently developed 
for the treatment of cancer and other non-communicable diseases, 
such as hypertension, psoriasis, asthma, and type II diabetes.
Taken together, traditional vaccines (inactivated or attenuated 
pathogens or toxins) have shown high immunogenicity and ability to 
stimulate the innate and adaptive immune system conferring long-
term memory and protection. Such high immunogenicity, particu-
larly where viral vaccines are concerned, is due to several factors 
such as the ability of the pathogen to replicate, the repetitive surface 
geometry of the virus and its particulate nature.19 Yet, several draw-
backs in the traditional vaccines have been raised by policymakers, 
including, but not limited to, safety issues from using the whole 
pathogen and the difficulty in mass production.
The 21st century has witnessed an advancement in molecular 
genetics, microbiology, immunology, and genomics techniques in 
applied vaccinology. Scientists have taken advantage of viruses by 
making them invaluable sources for generating safe and novel na-
noscale scaffolds termed virus-like particles (VLPs). VLPs are multi-
protein structures that resemble viruses in many characteristics.20 
The most important difference is that VLPs lack any genetic mate-
rial and therefore cannot replicate in host cells.21 Accordingly, VLPs 
serve as a premium vaccine platform overcoming several limitations 
of traditional vaccines such as poor definition, safety, or manufac-
turing obstacles. VLP platforms have led to considerable success in 
developing vaccines against human papillomavirus (HPV), hepatitis 
B virus (HBV), hepatitis E virus (HEV) as well as against malaria (for 
a review, see Ref. 21). Several other VLP-based vaccines are in pre-
clinical evaluation or undergoing clinical trials. In this review, we are 
discussing the basic 3Ds employed for VLP-based vaccine develop-
ment: design, delivery, and dynamics.
2  | DESIGN
2.1 | VLP geometry
Crick and Watson have stated in 1956 that “it is a striking fact 
that almost all small viruses are rods or spheres.” “These shells are 
constructed from a large number of identical protein molecules, of 
small or moderate size, packed together in a regular manner”.22 A 
key reason for such an arrangement is the small genomes of many 
viruses, in particular RNA viruses, which have no space to encode 
multiple proteins to build up a complex surface. As repetitiveness 
is unavoidable, the quasicrystalline nature of VLPs serves as a po-
tent pathogen-associated structural pattern (PASP) recognized by 
both innate and adaptive immune systems.23
The majority of viruses have a coat or a nucleocapsid consisting 
of multiple copies of single or just a few different kinds of struc-
tural proteins arranged in icosahedral or helical shapes. Coat pro-
teins (CPs) can self-assemble in artificial expression systems or in 
vitro spontaneously with or without the aid of nucleic acids (NA) or 
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scaffold proteins. According to purely mathematical principles, an 
icosahedron is built from 60 identical units arranged in 5-3-2 sym-
metry which is used to describe the rotation possibilities of an icosa-
hedron around an axis.24,25
Indeed, Crick and Watson predicted that icosahedral viruses 
must have at least 60 subunits.22 It has also been shown that an 
icosahedron with certain multiples of 60 subunits can be formed 
by incorporating subunits arranged in pentamers and hexamers.26 
However, in this case all subunits cannot be structurally identical 
as different environments (3D structures) exist within pentamers 
and hexamers. In practice, often a single CP species can adopt minor 
structural changes required for pentameric or hexameric contacts, 
a concept called quasi-equivalence. The number and arrangement 
of the different subunits of the virus coat can be classified using 
the quasi-equivalence theory described by Casper and Klug in 1962 
based on triangulation.27 The triangulation number (T) of the coat is 
determined by two integers h and k and is defined as T = h2+hk + k2.27 
Essentially, h and k correspond to the number of steps, which must 
be traveled along two axes in a hexagonal grid across the centers 
of pentameric and hexameric subunits in order to reach one vertex 
of icosahedron from another. Figure 1 illustrates icosahedral VLPs 
with T = 1 coat symmetry using porcine circovirus serotype 2 (PCV2) 
(Figure 1A) and T = 3 or T = 4 coat symmetry using HBV core (HBc) 
(Figure 1B,C). Hepatitis B virus has an unusual feature that it can 
be found in both T = 3 or T = 4 forms,28 albeit the infectious virions 
appear to be T = 4 only.29,30
It is interesting to note that most artificially designed synthetic 
VLPs consisting of a trimerizing and pentamerizing alpha-helical do-
main form T = 1 particle with 60 spikes. Due to several reasons listed 
in Table 1, small synthetic T = 1 VLPs may often be not ideal for a 
vaccine platform and T = 3 particles may be more favorable.
Examples of VLPs with subunits arranged in T = 3 configuration 
are ssRNA bacteriophages such as MS2, AP205, and Qβ as well as 
several plant viruses such as cowpea chlorotic mottle virus (CCMV) 
and cucumber mosaic virus (CuMV). There is an interesting differ-
ence between the ssRNA bacteriophages and ssRNA plant viruses. 
First, the folds of the CPs are entirely different in both cases, CPs of 
plant viruses have classical jelly-roll β-barrel fold,35 while CPs of ssRNA 
phages have a completely unique fold, not observed in any other pro-
teins. Secondly, the ssRNA-phage VLPs have subunit proteins of ap-
proximately 14 kDa36,37 while VLPs derived from plant viruses have 
subunit proteins of approximately 24 kDa.35 The likelihood to have a 
good TH cell epitope in a given protein is proportional to the number 
of amino acids (a.a.) present in the protein. VLPs derived from plant 
F I G U R E  1   Geometry of icosahedral 
viral particles. Three typical geometries 
of icosahedral viral capsids. From left to 
right, the panels show the color codes 
for the subunits and their approximate 
molecular weight; the external view of 
the viral capsid with the symmetry axes 
drawn over the icosahedron facet; and 
the disposition of the subunits over the 
hexagonal plan, with the triangulation 
path (h and k indexes) illustrated by 
black arrows. Vertical bars illustrate the 
approximate diameter of the particle. A, 
Capsid of porcine circovirus serotype 2 
(PCV2) observed in T = 1 configuration. 
PCV2 particles are formed by 60 identical 
subunits combined into 12 pentamers 
(illustrated here in different shades of 
purple just for clarity). From PDB 3JCI. 
B, Hepatitis B virus's (HBV's) capsid 
observed in T3 configuration. When in 
this configuration, HBV particles are 
formed by 60 of each subunit A, B, and 
C. From PDB 6BVN. c, HBV can also be 
observed in a T4 configuration, when it 
has an extra subunit D incorporated into 
its capsid arrangement. From PDB 6BVF
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viruses have a longer epitope sequence and therefore may be superior 
to bacteriophage VLPs in activating TH cells even though both have 
T = 3 symmetry.
In general, icosahedron architecture is more prevalent than the he-
lical shape. The definition of helical symmetry covers a broad area of 
geometries such as stacked rings, rods, or spring-shaped coils.38 The 
helical symmetry of VLPs can be measured using the formula P = μ × ρ 
where P refers to the pitch of the helix, μ is the number of structural 
units per turn of the helix, and ρ is the axial rise per subunit. A well-
known example of helical rod-shaped VLPs with hollow central channel 
is the tobacco mosaic virus–like particles.39 Interestingly, icosahedral 
VLP may easily be manipulated to form rod-shaped structures by in-
troducing few mutations. It has been shown previously that the ico-
sahedral Qβ-VLPs would assemble in rod-like particles after mutating 
five a.a. residues in the FG loop of the CP.40 Presumably, this happens 
because of overproduction of hexamers over pentamers which leads 
to formation of prolate icosahedrons, or rods, rather than regular ico-
sahedrons, as demonstrated also in the case when RNA phage coats 
of genogroups I and II are mixed together and reassembled in vitro.41 
Tobacco mosaic virus–based VLPs have proven in some studies to be 
an effective platform for the display of epitopes, successfully eliciting 
immune response against different target pathogens.42,43
TA B L E  1   Comparison between T = 1 and T = 3 VLPs
Characteristic T = 1 VLPs T = 3 VLPs Reference
B-cell receptor (BCR) 
cross-linking
Cross-linking 60 BCRs on B cells is likely at the 
threshold for optimal immune response
Cross-linking 180 BCRs on B cells results in a 
strong immune response
31
Distance between each 
displayed epitope on the 
surface of VLPs
The distance between each displayed epitope 
on the surface of T = 1 VLPs is usually less 
than 5-10 nm
The distance between each displayed epitope on 
the surface of T = 3 VLPs is approximately 5-10 
nm, which is ideal for BCR cross-linking and B 
cell activation
32
Interior cavity Small cavity Large cavity that allows packaging of large 
amounts of cargo such as nucleic acids, and Toll-
like receptor ligands for optimal activation of B 
and/or T cells
28,33,34
Abbreviation: B-cell receptor; VLPs, virus-like particles
F I G U R E  2   Cucumber mosaic virus 
(CuMV)–derived virus-like particle fused 
to universal tetanus toxoid (TT) T-cell 
epitope. General structural features of 
CuMVTT. A, Surface representation of 
viral capsid. Its T = 3 symmetry is formed 
by pentamers of subunit A (blue) and 
hexamers of subunits B (dark cyan) and 
C (light cyan). B, Cross section of the 
particle as shown in (A). The N-termini of 
both subunits B and C are colored orange 
to indicate the points of insertion of the 
tetanus toxoid epitope. C, The same 
view as in (A) but with the surface lysine 
residues liable to conjugation highlighted 
in red. D, Cartoon representation of a 
dimer formed by subunits B and C. All 
images generated from PDB 1F15
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Remarkably, the CPs of RNA phages can self-assemble not only 
into the classical T = 3 particles and the above-mentioned rod-like 
prolate icosahedrons, but also into T = 144 and T = 4 particles,45,46 
demonstrating the high plasticity of the assembly process. Generally, 
manipulating VLPs' structure allows to study the impact of size on 
drainage dynamics and magnitude of induced immune responses 
with one and the same VLP monomer, an avenue of research we are 
currently following.
2.2 | Binding and decorating functional 
molecules or ligands to VLPs
Bioorganic chemistry offers different artificial ways to modify 
proteins and other molecules. For successful chemical transfor-
mation of the biological molecules in VLP-based vaccine devel-
opment, several aspects should be considered: (a) The reaction 
should be efficient in an aqueous solvent with physiological pH 
values; (b) low concentrations of non-toxic reagents should be 
used; and (c) the tertiary and quaternary structure of the antigen 
and VLP should be preserved. Using different chemical modifi-
cation strategies, we have reached numerous proofs of concept 
in humans and animals. For example, vaccination with Qβ-VLPs 
displaying angiotensin II on the surface resulted in reduced blood 
pressure.47 A similar vaccine displaying nicotine has reduced 
smoking48 and a vaccine displaying full-length interleukin (IL)-1β 
reduced some signs of type II diabetes.49,50 A vaccine against 
Alzheimer's disease displaying the first six a.a. of Aβ1-42 reduces 
plaque load in mice and humans51,52 and is now in final clinical 
trials. The platform has also been tested for classical prophy-
lactic vaccines and display of the globular domain of influenza 
HA resulted in a vaccine candidate inducing protective titers in 
immunized humans.53,54 More recently, we have moved to treat 
companion animals using a new, immunologically improved plat-
form based on CuMV incorporating a universal T cell epitope 
derived from tetanus toxoid (TT) termed CuMVTT-VLPs.
55 The 
modified CuMVTT-VLPs is a T = 3 VLP identical to the parent 
CuMV-VLPs where subunits A are arranged in pentamers of five-
fold symmetry and three dimers of subunits B and C are arranged 
in hexamers in three-fold symmetry55 as illustrated in Figure 2A 
and Video S1.
The newly developed platform is thought to enhance the inter-
action between TH cells and B cells under normal as well as more 
challenging conditions such as those found in aged patients. This 
is due to the fact that preexisting immunity to the chosen TT epi-
tope is very broad in humans (and animals) as the peptide binds to 
essentially all human leukocyte antigen-DR isotype molecules and 
everybody has been immunized many times against TT.56,57 The 
TT epitope has been incorporated by genetic fusion to the CuMV 
viral envelope protein such that the icosahedral particle maintains 
its capacity to self-assemble without altering its T = 3 icosahedron 
geometry and without exposing the peptide on the VLP surface, 
avoiding interference of TT-specific antibodies (Figure 2B). This has 
been achieved by replacing the first 12 N-terminal a.a. with the 
TT epitope. The resulting CuMVTT-VLP platform has several advan-
tages, including the following: (a) It is adaptable to clinical appli-
cations; (b) CuMVTT-VLP monomers have a size of 24 kDa, which 
can serve as an additional source of  TH cell epitope; (c) the VLPs 
incorporate RNA derived from the E coli production strain serving 
as a Toll-like receptor (TLR)7/8 agonist; (d) the VLPs are stable for 
long time periods at 4°C and even 20°C; and (e) the platform is safe 
and highly immunogenic in mice, rabbits, dogs, cats, and horses and 
therefore is also expected to offer a good safety profile and immu-
nogenicity in humans.55,58
Using this new CuMVTT platform, we have generated a proof 
of concept for different preclinical vaccines as listed in Table 2. 
The most popular targets for modification on VLPs are accessible 
lysine residues (Lys) on their surface (Figure 2C). Lysine residues 
contain primary amines and can be modified at physiological 
pH values. N-hydroxysuccinimide (NHS) esters are commer-
cially available such as the commonly used cross-linker SMPH 
[succinimidyl 6-((beta-maleimidopropionamido)hexanoate)]. 
Ligand
Target 
species Disease/condition Reference
IL-5 Horse Insect-bite hypersensitivity 64,65
IL-31 Dog Atopic dermatitis 66
Fel d 1 Cat Allergic symptoms in humans, facilitating 
owner-cat interactions
67
NGF Mouse Pain in osteoarthritis 68
Ara h 2 Mouse Peanut allergy 69
E-DIII Mouse Zika virus infection 59
IL17A Mouse Psoriasis 55
Gp33 as a model 
antigen
Mouse Melanoma 62
TRAP Mouse Malaria 70
Abbreviation: CuMV, cucumber mosaic virus; NGF, nerve-growth factor; TRAP, thrombospondin-
related adhesive protein; VLPs, virus-like particles
TA B L E  2   CuMVTT-VLPs as a vaccine 
platform
160  |     MOHSEN Et al.
The heterobifunctional SMPH cross-linker has a reactive NHS 
group on one end and a maleimide group on the other end. The 
NHS group reacts with the Lys residue on VLPs while the ma-
leimide group reacts with a free sulfhydryl (SH) group in the 
target molecule forming a stable amide and thioether bond, 
respectively. SH exists on the side chain of cysteine residues 
(Cys) and can be incorporated easily in the target molecule for 
effective cross-linking.38 To link target proteins to VLPs with-
out introducing free Cys residues, the SH group can be intro-
duced in a protected form using the chemical cross-linker SATA 
(N-succinimidyl S-acetylthioacetate) which then can be exposed 
after treatment with hydroxylamine for conjugation reactions. 
SATA also contains an NHS ester facilitating the formation of an 
amide bond with Lys residues on VLPs. This simple method has 
been used to conjugate Zika virus–derived E-DIII protein to the 
immunologically improved CuMVTT-VLPs, which induced neu-
tralizing antibodies without enhancing Dengue virus infection.59 
Furthermore, canine IL-31 was conjugated to CuMVTT-VLPs to 
treat chronic itch in dogs. Several VLP-based vaccines in pre-
clinical and clinical studies are based on these simple chemical 
methods.20,60 However, for the development of a personalized 
VLP-based vaccine in cancer settings, we have recently used Cu-
free click chemistry method to couple peptides to CuMVTT-VLPs 
or Qβ-VLPs. The method showed efficacy and induced specific T 
cell response protective against tumor progression in an aggres-
sive transplanted melanoma murine model.61,62 This chemistry 
may be favorable over SMPH as Cys within T cell epitopes may 
react with SMPH resulting in epitope inactivation. Additionally, 
non-reacting SMPH may be toxic, requiring complex purification 
processes which may not be optimal for rapid generation of per-
sonalized cancer vaccines. Cu-free click chemistry is a bio-or-
thogonal chemistry63 and is commercially available, in the form 
of, for example, dibenzocyclooctyne-NHS ester. This cross-linker 
reacts with Lys residues on VLPs to incorporate a cyclooctyne 
moiety which reacts with an azide-labeled molecule to form a 
stable triazole bond without a Cu catalyst. This method enables 
rapid, safe, and efficient coupling for good manufacturing prac-
tice–produced modified VLPs.
Many antibacterial vaccines are based on conjugation of carbohy-
drates to carrier proteins. VLPs are obvious candidates for such carrier 
proteins as they enhance the immunogenicity of conjugated antigens 
greatly.71 However, production of bacteria-derived carbohydrates is 
expensive and comes with a number of obstacles, for example, grow-
ing large amounts (kg) of dangerous bacteria. We therefore consider it 
a major breakthrough that it has recently been possible to glycosylate 
VLPs in vivo with defined bacterial carbohydrate structures in the cy-
toplasm of E coli. Yields of such VLPs are high, and the cost of goods 
is in orders of magnitude lower than conventional production.71 Due 
to the low cost of goods, this opens up the possibility to immunize 
farm animals against bacterial infections using VLPs displaying carbo-
hydrates. This may represent a major step for the one-health concept 
and may allow to substantially reduce antibiotic resistance spread by 
farm animals treated with antibiotics.
2.3 | VLPs and nucleic acids (NAs)
VLPs can assemble on a polyvalent scaffold of NA, usually RNA. 
Generally, the CP of viruses play a role in organizing the pack-
aged NA; conversely, NA plays a role in structure's assembly and 
immunogenicity of VLPs. A highly ordered NA structure can be 
seen in bean pod mottle virus,72 tobacco necrosis virus,73 or no-
daviruses.74 Bacterial expression systems such as E. coli is the 
most widely used system for the production of non-enveloped 
VLPs. VLPs self-assemble on prokaryotic RNA (pRNA) during the 
expression process.75 By way of example, CuMVTT-VLPs can suc-
cessfully be expressed in E coli host. Cryo-electron microscopy 
analysis of the VLPs demonstrates additional electron density in 
its interior cavity. This ordered structure most likely reflects the 
tightly bound host pRNA suggesting its role in stabilizing the sub-
units of the VLPs.55 Assembly studies are vital to understanding 
virus formation in biological settings which facilitates the pack-
aging of non-viral materials for VLP-based vaccine development. 
Flock house virus (FHV) was used to study the encapsidation pref-
erence of specific RNA via next-generation sequencing experi-
ments. It has been shown that the native viral particle contains 
1% host-derived RNA and 99% viral genomic RNA. In contrast, 
recombinant FHV-VLPs can encapsidate a larger percentage of 
host RNA in insect cell culture.38 Other VLPs have been shown 
to encapsidate different host RNAs, including messenger (mRNA), 
transfer (tRNA), or ribosomal (rRNA), as well as RNA encoding 
the CP.76 The addition of a potent vaccine adjuvant is an essential 
strategy to activate antigen-presenting cells (APCs) mainly den-
dritic cells (DCs) for induction of T cell responses. Therefore, the 
interior surface of VLPs is often exploited to package different 
TLR ligands such as ssRNA, dsRNA, or CpGs.77,78 To achieve this, 
the host NA has to be removed first. This is typically accomplished 
by the disassembly/reassembly method (Figure 3A) or by the en-
zymatic digestion method of the host NA and repackaging with 
the desired one (Figure 3B).
A recent study performed by us has used the disassembly/
reassembly method to compare three different types of RNA 
packaged inside Qβ-VLPs displaying the M2 ectodomain from 
influenza virus as an antigen. pRNA, eukaryotic RNA (eRNA), 
or tRNA has been used, and the results indicated that the type 
of packaged RNA can alter the induced protective humoral im-
mune response in a murine influenza model. Specifically, pRNA 
packaged in Qβ-VLPs induced the most protective IgG2b/c, 
while eRNA showed more shift to IgG1 with less protection. The 
study provided evidence that the shifting of the Ab response is 
dependent on TLR7 and it rules out the role of the cytoplasmic 
mitochondrial antiviral signaling protein (MAVS) and retinoic 
acid–inducible gene-like receptor (RIG-1). Such findings are cru-
cial for rational design of VLP-based vaccine aiming at inducing 
the most desirable and strong B cell response.79
The second method is the enzymatic digestion method, which 
is achieved by treating the VLPs with RNase to remove the RNA. 
Subsequently, the empty coat VLP can be repackaged with small 
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oligonucleotides of choice, yielding a loaded VLP. This method 
has been used in different studies utilizing the bacteriophage 
Qβ or HBcAg.61,80,81 Alternatively, the desired NA can be pack-
aged in VLPs during the cultivation process of the recombinant 
protein in the host system. Polyomavirus JC VLPs were tested 
to package a model plasmid of 9 kb directly when expressed in 
E coli cells.82 VLPs, however, are usually poor vehicles for trans-
gene expression, as they are degraded in endosomes and DNA 
may not easily reach the cell nucleus. Indeed, CpGs and RNA are 
ideal cargo, as they are sensed by TLR9 and TLR7/8 localized 
endosomes, where the ligands are released after protein shell 
degradation.
3  | DELIVERY
3.1 | Routes of administration
The protection conferred by a VLP-based vaccine is essentially de-
pendent on the induced humoral and/or cellular immune response. 
However, the science of vaccine administration route is a poorly de-
veloped and described area. This is mainly due to the fact that vac-
cine trials lack standardized comparison of the injection site, needle 
length, or injection techniques.
Evidence-based medicine aims at improving the quality of health 
methodologies. Thorough careful assessment of published clinical 
F I G U R E  3   Virus-like particle (VLP) NA exchange. Two methods for exchanging VLP nucleic acids (NAs). A, Particle disassembly and 
reassembly. In this method, the particle is initially disassembled, the endogenous NA is removed, and a new NA is repackaged into the VLP 
during the reassembling process. In the order indicated by the arrows, the images represent the exterior of the particle at the beginning 
of the process; the interior of the particle packaged with endogenous NA “X”; disassembled particle being reassembled, after removal of 
NA “X,” in the presence of exogenous NA “Y”; the interior of the particle packaged with NA “Y”; and the external view of the particle at the 
end of the process. B, Enzymatic digestion and infusion. Instead of being washed out after the particle disassembling, in this method the 
endogenous NA is eliminated by enzymatic digestion. The exogenous NA is then repackaged into the VLP by diffusion, which is facilitated 
by the high porosity of the particle's surface. In the order indicated by the arrows: the interior of the particle packaged with endogenous 
NA “X”; digestion of NA “X” and diffusion of exogenous NA “Y” into the VLP; and the interior of the particle packaged with NA “Y.” Images 
generated from unrelated protein data bank (PDB) files 5KIP and 1Y0Q
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data regarding the route of vaccine administration subcutaneous 
(SC) vs intramuscular (IM) revealed that the current practice is based 
on tradition rather than clinical data.83,84 Traditionally, vaccines 
were injected SC until it was noticed that adjuvanted vaccines such 
as Alum could induce unacceptable local reactions at the injection 
site in humans and injections were changed to IM, most probably 
because the injection site reactions were less visible. Indeed, the 
four licensed VLP-based vaccines as well as the first licensed malaria 
VLP-based vaccine RTS,S (Mosquirix™) use IM route of administra-
tion as shown in Table 3.
When comparing SC to IM routes of vaccine injection, IM has 
shown a faster rate of absorption of administered materials.85 This 
is due to the fact that muscles are more abundant with larger blood 
vessels than SC tissues which have lower vascularity. This may result 
in slower mobilization of the vaccine and thus slower processing of 
the antigen.
Under normal non-inflamed conditions, very few resident im-
mune cells such as APCs are found in muscles.86 Administering 
vaccines such as VLPs induces a transient pathological condition 
in the muscle resulting in infiltration by immune cells such as mac-
rophages, neutrophils, DCs, and lymphocytes.87 Additionally, myo-
cytes also react to the pathological condition by expressing different 
cytokines and chemokine receptors such as IL-6, IL-1, IFN-γ, CCR2, 
CCR4, and CCR10.88 Such transient reactions rarely cause serious 
adverse effects at the injection site. In a series of 26,294 adults, of 
whom 46% received an IM injection, only 0.4% had a local injec-
tion site reaction.89 On the other hand, SC injections can result in 
abscesses and granulomas in humans.90-93 However, in preclinical 
studies with rodents, the SC is more commonly used route of in-
jection than IM. This is because of the simplicity of the method and 
the possibility of delivering larger volume of the vaccine and more 
freedom in choosing the injection site.94 Additionally, using the SC 
route for VLP-based vaccines did not result in any adverse effects in 
murine models. Regarding the induced immune response of a VLP-
based vaccine when comparing the SC vs IM route of injection, we 
have previously shown that the SC route of injection is effective at 
inducing a protective B or T cell response in a wide range of preclini-
cal studies.61,64,68,95-97 Furthermore, the SC and IM routes of admin-
istration of an experimental VLP-based vaccine in humans resulted 
in similar antibody (Ab) titers.98 These data indicate that SC route of 
immunization may also have its merits.
There is evidence that intradermal vaccination may be superior 
to other routes of immunization. Indeed, a study published in 2009 
has used a near-infrared fluorescent dye (NIR) coupled to simian-hu-
man immunodeficiency virus (SHIV)–like particles to track their 
movement in SKH-1 mice using different immunization routes. The 
study has observed that intradermal immunization with SHIV-VLPs 
involved a broader range of lymph nodes (LNs). This resulted in the 
production of the highest Ab titers confirmed by the increase in ger-
minal centers in the spleen as well as the highest antigen-specific 
cytotoxic T-lymphocyte (CTL) response.99 Similar findings were ob-
served in humans using influenza virus vaccines, where intradermal 
immunization retained full immunogenicity even at up to five times 
lower vaccine dose.100 In contrast to Ab responses, we have com-
pared the induction of MelanA-specific T cells in a phase I/II study 
for stage II-IV melanoma patients upon SC vs intradermal vs intran-
odal injection and found no difference in responses.60
With the advent of oncolytic viruses injected directly into the 
tumor, this route is also investigated for VLPs. The bacteriophage 
Qβ-VLPs filled with A-type CpGs (originally called by us QbG10 
now CMP-001) have been used for intratumoral injections and are 
currently being examined in combination with systemic anti-PD-1 
checkpoint inhibition in two different clinical trials for patients with 
advanced melanoma who showed resistance to anti-PD-1 treatment. 
The recently collected data from the ongoing trials show manage-
able toxicity and potential to reverse the resistance to anti-PD-1 
(NCT02680184/NCT03084640). Lizotte et al have investigated a 
further route of application and shown that inhalation of cowpea 
mosaic virus (CPMV)–like particles caused regression of an estab-
lished B16F10 lung melanoma by generating an efficient systemic 
anti-tumor immune response. The study has shown that an im-
portant player of the generated anti-tumor response in the tumor 
microenvironment was neutrophils which could rapidly take up 
CPMV-VLPs.101 Furthermore, the authors have shown that intratu-
moral injection of CPMV-VLPs is also effective in treating dermal 
B16F10 melanomas, forming central tumor necrosis.101
A combination of different routes has also been investigated 
using human immunodeficiency virus (HIV)–like particles which re-
semble the virus envelope protein in its native conformation. It has 
been shown that that priming with HIV-VLPs intranasally followed by 
sub-cheek route for boosting resulted in the highest titers of specific 
immunoglubulin B (IgG) compared to the other combination of prim-
ing and boosting routes used (intradermal-intranasal-sub-cheek).102
Mucosal Ab responses may be an interesting case where the 
route of immunization is concerned. SC immunization of mice with 
RNA-loaded VLPs leads to strong systemic immunoglobulin M (IgM), 
immunoglobulin A (IgA), and IgG responses. While the IgG response 
is TH cell–dependent, both IgM and IgA antibodies are TH cell–in-
dependent.103 In contrast, mucosal IgA responses in the lung were 
absent while strong mucosal IgG responses are observed. Mucosal 
immunization, on the other hand, results in strong mucosal IgA and 
IgG responses. IgA responses are heavily dependent or TLR7/8 or 
TLR9 ligands packaged in VLPs for mucosal and systemic IgA. Again, 
systemic and mucosal IgA responses are regulated differently, as 
TA B L E  3   Route of immunization of the licensed VLP-based 
vaccines.
VLP vaccine License date
Route of 
immunization
Gardasil USA, 2006 IM
Cervarix USA, 2009 IM
Recombivax USA, 1983 IM
Hecolin China, 2011 IM
Mosquirix™ EMA, 2015 IM
Abbreviations: IM, intramuscular; SC, subcutaneous; VLP, virus-like 
particle
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systemic IgA requires TLR7/8 or TLR9 in B cells, while mucosal IgA 
responses do not require TLR7/8 or TLR9 in B cells but DCs rather, 
which induce IgA in a Transforming growth factor beta (TGF-β)- and 
BLyS-dependent fashion.104 Hence, systemic IgA responses are sim-
ilarly regulated as subclass switching to IgG2a as they also require 
TLR expression in B cells rather than DCs.105 Recently, it has been 
shown that administering the influenza VLP vaccine (M2e5x VLP) in-
tranasally facilitated mucosal delivery of the vaccine and can induce 
a broad cross-protection, prevent weight loss, lower the viral load, 
attenuate the inflammatory reaction and induce germinal center 
formation. The study indicated that the observed protective role is 
managed by B cells as well as CD8+ and CD4+ T cells.106
In conclusion, it seems that VLPs efficiently reach lymphoid or-
gans from most injection sites and prime similar but not always iden-
tical immune responses.
4  | DYNAMIC S
As discussed above for the delivery, rules for induction of Ab vs T 
cell responses may differ and both design and delivery of VLPs have 
important consequences for the dynamics of the immune response.
4.1 | VLP-based vaccine formulation
VLP-based vaccines are made of a restricted number of antigens 
or individual components of the targeted pathogen, hopefully able 
to confer a protective and/or a therapeutic effect. Accordingly, the 
protective epitope must be displayed in its native form, at least if 
the induction of Abs is the desired response. This may be different 
for T cell-based vaccines, where native display of the epitope is not 
required. Furthermore, VLP-based vaccines must be optimized for 
antigen density, dose, and prime/boost interval to obtain a potent 
Ab response. Unexpectedly, a recent study has demonstrated that 
such criteria are not necessary for achieving high-avidity T cell re-
sponses.107 Indeed, requirements for vaccines designed to induce 
Abs (most prophylactic vaccines and vaccines targeting endogenous 
molecules for their blockage) differ from vaccines aiming to induce 
T cell responses. In contrast to vaccines against simple viruses, most 
vaccines targeting complex pathogens will need to induce B and ef-
fector T cells. Table 4 summarizes design requirements for optimal 
delivery to cause a dynamic response of desired specificity.
4.2 | B cells and antibodies
B cell responses are optimally stimulated by repetitive particles 
displaying native epitopes and which are associated with a potent 
adjuvant for B cells. VLPs loaded with RNA or CpGs and display-
ing full-length antigens on their surface are therefore ideal for in-
duction of Ab responses. Depot formation may be less important 
for vaccines aiming to induce Abs, since VLPs are recognized by 
natural IgM antibodies which recruit C1q and lead to deposition 
on follicular DCs (FDCs).108 FDC-associated antigen is essentially 
an endogenous antigen depot that can persist for weeks and 
months.109 As discussed above, RNA or CpG-loaded VLPs trig-
ger strong IgG2a and IgA responses but require TLR expression 
in B cells, not DCs.104,110 Hence, adjuvants for B cells should be 
physically associated with the VLPs to recognize antigen and trig-
ger B cells directly. As discussed earlier, the type of RNA pack-
aged in VLPs is important to enhance B cell responses. We found 
that pRNA was clearly superior to eRNA or tRNA. Cytosolic sen-
sor RIG-I and MAVS had no influence on the magnitude of the 
 Antibody (Ab) T cells
Antibody (Ab) and 
T cells
Antigen Native display Irrelevant Native display
VLP scaffold important 
for
Repetitive display Particulate for DC 
targeting
Both
Adjuvants Activation of B cells 
(and DCs)
Activation of DCs Both
Adjuvants formulation Physically linked to 
VLPs
Formulated in 
depot and/or 
codelivered with 
adjuvant33,127
Physically linked 
to VLPs and 
formulated in 
depot adjuvants
Depot formation Not very important 
as antigen persists 
on FDCs
Depot for long-
term stimulation
Depot for long-
term stimulation; 
importantly, the 
adjuvants may 
not compromise 
antigen structure
Size <200nm for effective 
drainage to LN
Antigens may be 
larger
<200 nm for 
effective drainage 
to LN
Abbreviation: DCs, dendritic cells; Follicular dendritic cells (FDCs).
TA B L E  4   Requirements for optimal 
induction of Ab or T cell responses or both
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response, and TLR7 itself may be able to distinguish between 
prokaryotic and eukaryotic RNA.
Conventionally, vaccines aim to induce long-lived Ab responses 
rather than memory B cells.111 We have recently shown that mem-
ory B cells that have been induced in the presence of TLR7 stimu-
lation can rapidly differentiate into secondary plasma cells which 
produce very high levels of Abs.112,113 Again, TLR7-stimulation 
was necessary to cause differentiation of memory B cells into 
secondary plasma cells. The response of secondary plasma cells 
peaked within a few days after antigenic challenge and produced a 
very rapid first wave of Abs. Interestingly, these secondary plasma 
cells were not long-lived and did not differentiate into a new wave 
of memory B cells. In contrast, they essentially all died within 
6 days. Indeed, all memory B cells generated during the second-
ary response were derived from naive B cells. Hence, a first wave 
of antibodies is produced very rapidly but the immune system 
mounts a primary B cell response under the protective shield of 
the secondary plasma cell–derived Abs.114 This ensures that orig-
inal antigenic sin is kept minimal and allows the immune system 
to optimally respond to slightly evolved, re-emerging pathogens 
that may not be optimally recognized by the existing Ab specifici-
ties. Hence, induction of memory B cells with the ability to rapidly 
differentiate to secondary plasma cells may be an important, cur-
rently underestimated goal of vaccination.
4.3 | T cell responses
A VLP-based vaccine displaying T cell epitopes can elicit a strong TH 
1 as well as CTL responses despite the fact that they do not carry 
any genetic material for replication.115-120 The particulate nature of 
VLPs allows them to be cross-presented on major histocompatibility 
class I (MHC-I) molecules as well as on major histocompatibility class 
II (MHC-II) for effective priming of CD8+ and CD4+ T cells, respec-
tively.121,122 As mentioned earlier, the type of NAs packaged in the 
VLPs plays a vital role in determining the desired immune response. 
Non-methylated CpGs, TLR9 ligands, are potent stimulators of the 
innate immune system characterized by upregulating costimula-
tory molecules, cytokines, and chemokines.123 Our recent study 
has investigated the transcriptional signature in DCs from mice vac-
cinated with Qβ packaging TLR7/8 or TLR9 ligands and displaying 
H-2Db gp33 epitope. The most striking observation involved CCL2 
chemokine which was distinctly expressed in DCs 24 hours follow-
ing immunization with Qβ(type-B CpGs)-p33, a potent TLR9 ligand. 
The identified pathway is thought to play an important role in DCs 
activation and subsequent induction of potent (CTL) response.124
Administering synthetic CpGs directly in vivo may result in unfa-
vorable outcomes such as toxic shock, auto-Ab production, inflam-
mation, or the induction of anti-DNA antibodies.125 Such obstacles 
can be easily overcome by packaging CpGs in VLPs which indeed 
reduces side effects and results in an efficient CTL response.20,81,119 
The dogma for an optimal response in VLP-based vaccines is that 
both antigen and adjuvant should be delivered in the same VLP.81,126 
However, we have shown that this is not always necessary; adju-
vants such as CpGs can be packaged in separate VLPs and mixed 
with the vaccine prior to administration without the need of physi-
cal linkage and would still generate a strong CTL response.33 Similar 
results were obtained when admixing E7 protein oligomers derived 
HPV with Qβ-VLPs loaded with CpGs.127 The formula could induce 
a protective CD4+ and CD8+ T cell response in a HPV mouse model. 
These findings indicate that physical linkage of both antigen and ad-
juvant in a VLP-based vaccine may not be necessary for effective T 
cell activation. In contrast, simple, admixing VLPs did not enhance 
B cell responses, indicating the rules for T and B cell responses are 
different (see also Table 4).
Adjuvants may enhance the immune response by several mech-
anisms such as prolonging the release of the antigen at the injection 
site and upregulating different cytokines, chemokines, and costim-
ulatory molecules. This results in increased maturation and antigen 
uptake by APCs for effective presentation on MHC-II or by the acti-
vation of inflammasomes and TLRs.128 TLR agonists packaged inside 
VLPs are recognized by pattern recognition receptors (PRRs) while 
particulate adjuvants such as Alum are considered damage-associ-
ated molecular patterns (DAMPs). As discussed above, adjuvants 
may also act directly on B cells, as, for example, RNA and CpGs stim-
ulating TLR7/8 and TLR9, respectively.
We have recently harnessed the physiological properties of the 
lymphatic system by formulating CuMVTT-VLPs displaying H-2D
b 
gp33 peptide derived from lymphocytic choriomeningitis virus with 
a biodegradable microcrystalline tyrosine depot adjuvant (MCT). 
CuMVTT-VLPs are nanoparticles with packaged RNA as TLR7/8 ag-
onist while MCT is a micron-sized depot-forming adjuvant capable 
of activating the inflammasome. Such formulation has increased the 
resultant specific CTL response in a murine melanoma model.62 The 
novel immune enhancer can also be translated to humans as VLPs 
used are well defined and the micron-sized adjuvants have been 
used for decades in allergen-specific desensitization.129 This mi-
cron-/nano-hybrid system harnesses the properties of the lymphatic 
system optimally, as the micron-sized MCT cannot enter the lym-
phatics and only the slowly released nanoparticles are actually able 
to do so, resulting in a slow-release depot of VLPs.
5  | CONCLUDING REMARKS
The 3Ds of vaccinology, design, delivery, and dynamics, are 3 key 
components for the efficient generation of a protective vaccine. 
Optimal design allows repetitive display of native antigens on VLPs 
loaded with TLR ligands for direct stimulation of B cells for IgG 
and IgA production as well as enhanced T cell responses. Optimal 
delivery may be key for inducing mucosal responses, or enabling 
dose sparing and mediating direct oncolytic activity if applied into 
the tumor. Optimally designed and delivered vaccines will result in 
optimally dynamic immune responses, with the desired outcome of 
strong T cell responses, highly specific Ab responses, and optimal 
clinical efficacy.
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